Highest-materiality recent filing
Pasithea receives Nasdaq bid price deficiency notice; 180-day cure period
Received Nasdaq notice on Feb 20, 2026 for failing minimum $1.00 bid price for 30 consecutive business days.
Authorized common stock increased from 100M to 500M shares via certificate amendment filed Jan 28, 2026.
Pasithea raises ~$60M in public offering of common stock and pre-funded warrants
Gross proceeds of $60.0M; net proceeds of ~$54.9M after fees and expenses.
BRAF V600E melanoma patient achieved -31.9% tumor reduction on PAS-004 monotherapy; remains on trial >11 months.
Pasithea Therapeutics receives Nasdaq minimum bid price non-compliance notice
Nasdaq notified company on June 23, 2025 that common stock bid price closed below $1.00 for 30 consecutive business days.
Pasithea closes $5M public offering, receives $1.3M from warrant exercises
Offered 3,571,428 units at $1.40/unit (common stock or pre-funded warrant + Series C/D warrants); gross $5M.
Pasithea Therapeutics raises $5M in private placement of pre-funded warrants and Series A/B warrants
Gross proceeds ~$5M; net proceeds ~$4.5M after fees and expenses.
No treatment-related adverse events or dose-limiting toxicities observed in first 2 cohorts (n=6); no rash or GI toxicity.
Pasithea shareholders approve classified board, supermajority vote, eliminate written consent
Stockholders approved classifying Board into three classes with staggered 3-year terms; removal only for cause.
Pasithea Therapeutics announces 1-for-20 reverse stock split effective January 2, 2024
Reverse split ratio of 1-for-20; authorized shares reduced from 495M to 100M.
Pasithea completes tender offer: buys 5.32M shares at $0.70; post-offer shares 20.8M
All 5,323,451 validly tendered shares accepted for purchase at $0.70 per share, no proration.
Pasithea Therapeutics receives Nasdaq extension to Jan 15, 2024 for bid price compliance
Nasdaq granted 180-day extension to January 15, 2024 to regain $1.00 minimum bid price compliance.
Pasithea announces $4M tender offer for common stock at $0.70/share, expected Q3 2023
Board authorized $4.0M tender offer to repurchase up to ~5.7M shares at $0.70 per share in cash.
Pasithea Therapeutics receives Nasdaq deficiency notice for minimum bid price non-compliance
Received Nasdaq notice on Jan 19, 2023 for failure to meet $1.00 minimum bid price rule (Nasdaq 5550(a)(2)).
Pasithea settles with Camac Group; to repurchase 3.2M shares at $1.0003, standstill 3 years
Will buy back 3,205,282 shares (11% of outstanding) at $1.0003 per share (trailing 5-day VWAP).
Pasithea acquires AlloMek for $1.05M cash, 2.7M shares + warrants; adds MEK inhibitor CIP-137401
Total deal value includes $1.05M cash, 2.7M restricted shares, 1M warrants at $1.88, up to $5M milestones, and royalties.
Pasithea Therapeutics files Alpha-5 Integrin financials for acquisition closed June 21, 2022
Alpha-5 (preclinical-stage, ALS/neuroinflammatory mAbs) had no revenue and $1.7M net loss for FY 2021.
Pasithea acquires Alpha-5 integrin in $3.75M stock-and-warrant deal for ALS/neurology pipeline
Pasithea acquires all equity of Alpha-5; total consideration: 3,260,870 shares of KTTA common stock at $1.15/share (11% premium to June 21 close) plus 1M warrants at $1.88 exercise price for 5 years.
Pasithea Therapeutics CFO Stanley Gloss passes away; search for replacement underway
Stanley Gloss, CFO of Pasithea Therapeutics, passed away on June 7, 2022.
Pasithea Therapeutics prices $30.4M private placement of 8.68M shares and warrants at $3.50/unit.
Gross proceeds $30.4M from sale of 8.68M shares and accompanying warrants at $3.50 per unit.
On May 4, 2026, Pasithea Therapeutics Corp. (the “Company”) announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026.
Effective October 11, 2022, Daniel Schneiderman was appointed to serve as the Chief Financial Officer of the Company.
On September 14, 2022, Dr. Yassine Bendiabdallah resigned from the board of directors (the “Board”) of Pasithea Therapeutics Corp. (the “Company”).
Concurrently, the Board appointed Alfred J. Novak to the Board and to its audit committee.
On June 7, 2022, Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp. (the “Company”), passed away.
Max materiality 0.75 · Median 0.55 · Most common event other_material